A quinoxaline derivative with antifungal activity and its application
By developing quinoxaline derivatives with antifungal activity, the problems of large side effects and serious drug resistance of existing antifungal drugs have been solved, especially in terms of cryptococcal meningitis, compounds A1 and A3 show both in vitro and in vivo It has excellent results and provides new drug options for treating Cryptococcus infection.
Patent Information
- Application Number
- CN202310447366.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-04-24
AI Technical Summary
Existing antifungal drugs have great toxic side effects and serious drug resistance, which cannot effectively meet the clinical treatment needs of invasive fungal infections, especially the treatment of cryptococcal meningitis is not effective.
A quinoxaline derivative with antifungal activity was developed, with a specific structure of N-(3-chlorophenethyl)-2',3',5',6'-tetrahydro-1H-spiro[quinoxal] Lin-2,4'-thiran]-3-amine and similar compounds have shown significant selective antifungal activity against Cryptococcal neoformans and Cryptococcal Gothicococcus, especially in cryptococcus meningitis infection Good efficacy was shown in the model.
Compounds A1 and A3 show high antibacterial activity against Cryptococcal in vitro, and significantly reduce the amount of caesarean in the brain of mice through intraperitoneal injection and oral administration in vivo, providing a new antifungal drug selection, which is superior to some existing drugs. Such as FLC.
Smart Images

Figure CN116589479B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular, relates to a quinoxaline derivative with antifungal activity and application thereof. Background Art
[0002] Invasive fungal infections are increasingly becoming a public health issue of widespread concern worldwide, with their morbidity and mortality rates increasing year by year. The main pathogenic fungi of invasive fungal infections include Candida, Cryptococcus, Aspergillus and Pneumocystis, which are prone to occur in people with low immunity or impaired immune systems. Among them, cryptococcal meningitis caused by Cryptococcus can also occur in people with normal immunity. At present, there are four main types of drugs used clinically to treat invasive fungal infections: azoles (such as fluconazole), polyenes (such as amphotericin B), echinocandins (such as caspofungin), and pyrimidines (such as 5-fluorocytosine). Most of the existing antifungal drugs have problems such as large toxic side effects and severe drug resistance, and cannot meet the clinical treatment needs of invasive fungal infections. Therefore, there is an urgent need to develop new antifungal drugs with a new mechanism of action. Summary of the invention
[0003] The first object of the present invention is to provide a quinoxaline derivative having antifungal activity.
[0004] The second object of the present invention is to provide a use of the quinoxaline derivative having antifungal activity in the preparation of antifungal drugs.
[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0006] The first aspect of the present invention provides a quinoxaline derivative or a pharmaceutically acceptable salt thereof having antifungal activity, the general structural formula of which is one of the following structures:
[0007]
[0008] in,
[0009] R1 is selected from hydrogen, -COOR 15 , -CN;
[0010] R2 is selected from hydrogen, -COOR 15 , -CN;
[0011] R3 is selected from hydrogen, -COOR 15 , -CN;
[0012] R4 is selected from hydrogen, -COOR 15 , -CN;
[0013] R 15 is selected from hydrogen, methyl, ethyl;
[0014] m is a positive integer selected from 1 to 5 (e.g., 1, 2, 3, 4, 5);
[0015] R5 is selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0016] R6 is selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0017] R7 is selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0018] R8 is selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0019] R9 is selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0020] R 10 is selected from hydrogen, methyl, ethyl;
[0021] n is a positive integer selected from 1 to 5 (e.g., 1, 2, 3, 4, 5);
[0022] R 11 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0023] R 12 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0024] R 13 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine);
[0025] R 14 Selected from hydrogen, halogen (fluorine, chlorine, bromine, iodine).
[0026] Most preferably, the structure of the quinoxaline derivative having antifungal activity is selected from one of the following structures:
[0027]
[0028]
[0029] The second aspect of the present invention provides a use of the quinoxaline derivative having antifungal activity or a pharmaceutically acceptable salt thereof in the preparation of an antifungal drug.
[0030] The fungus is selected from Cryptococcus neoformans H99 (C.neoformans ATCC 34877), Cryptococcus gattii ATCC 14116), Candida albicans SC5314 (C.albicans 0304103), Candida glabrata 9073, Candida lusitaniae 9150, Candida tropicalis 10186, and Candida krusei 10153.
[0031] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:
[0032] The quinoxaline derivatives with antifungal activity provided by the present invention have good anti-cryptococcal activity, and some compounds show excellent selective antifungal activity against cryptococci (including Cryptococcus neoformans and Cryptococcus gothiformis) in vitro. The present invention evaluates the antifungal activity of preferred compounds A1 and A3 at the animal level, and the results show that compounds A1 and A3 can significantly reduce the brain bacterial load of mice in a cryptococcal meningitis infection model, and compound A3 has good in vivo efficacy against cryptococcal meningitis infection by intraperitoneal injection and oral administration. Therefore, the compounds provided by the present invention can be used to prepare antifungal drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 Schematic diagram of the time-growth curve results of compounds A1 and A3 acting on Cryptococcus neoformans.
[0034] Figure 2 Schematic diagram of the inhibitory effects of compounds A1 and A3 on biofilm formation of Cryptococcus neoformans.
[0035] Figure 3 Schematic diagram of the experimental results of the mouse cryptococcal meningitis infection model of compounds A1 and A3. DETAILED DESCRIPTION
[0036] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.
[0037] The reagents and raw materials used in the following examples are all commercially available or can be prepared according to literature methods. Experimental methods without specific conditions are carried out under conventional conditions or under conditions recommended by the manufacturer.
[0038] The preparation method of compound A1-A10 is as follows:
[0039]
[0040] Reagent conditions: (a) 50°C, 12h; (b) THF, POCl3, Et3N, 2h; (c) ZrCl4, EtOH, 4h.
[0041] Example 1
[0042] N-(3-Chlorophenethyl)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-3-amine (Compound A1)
[0043] N-(3-Chlorophenethyl)formamide (3a)
[0044] Ethyl formate (2, 8.5 g, 0.12 mol) was added to a 250 mL eggplant-shaped reaction bottle, and then 3-chlorophenylethylamine (1a, 700 mg, 4.50 mmol) was added. The two were heated and stirred in a 50 ° C oil bath for 12 h, and monitored by TLC (PE / EA=3 / 1). After the reaction was completed, the reaction solution was cooled and concentrated under reduced pressure to obtain a light yellow viscous oil, namely intermediate 3a (750 mg, 4.08 mmol), with a yield of 90.7%. The crude product was used directly in the next step without purification.
[0045] 1-Chloro-3-(2-isocyanoethyl)benzene (4a)
[0046] In 20mL tetrahydrofuran as solvent, the intermediate 3a (750mg, 4.08mmol) was dissolved, and triethylamine (1.75g, 0.02mol) was stirred at 0°C, and phosphorus oxychloride (730mg, 4.76mmol) was slowly added dropwise. After 1h, the mixture was returned to room temperature and stirred for 1h. TLC monitoring (DCM / MeOH=50 / 1). After the reaction was completed, the reaction solution was washed with saturated NaCl solution (50mL×3) and extracted with ethyl acetate (30mL×3). The organic layer was collected and concentrated under reduced pressure to remove ethyl acetate. Separation and purification by silica gel column chromatography (DCM / MeOH=50 / 1) gave an odorous light yellow liquid, namely intermediate 4a (500mg, 3.02mmol), with a yield of 74.0%.
[0047] N-(3-Chlorophenethyl)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-3-amine (A1)
[0048] The intermediate 4a (300 mg, 1.81 mmol), o-phenylenediamine (5a, 193 mg, 1.81 mmol) and tetrahydrothiopyran-4-one (6, 210 mg, 1.81 mmol) were placed in a 250 mL eggplant-shaped reaction bottle containing 20 mL of ethanol, and zirconium tetrachloride (42 mg, 0.18 mmol) was added, and stirred at room temperature for 4 h, and monitored by TLC (DCM / MeOH=50 / 1). After the reaction was completed, the ethanol was removed by concentration under reduced pressure. 50 mL of ethyl acetate was added to dissolve, ultrasonicated, and filtered. The filter cake was rinsed with ethyl acetate (50 mL×3), then rinsed with clean water (50 mL×3), dried, and then purified by preparative liquid phase (MeCN / H2O=55 / 45, 65 / 35, 75 / 25) to obtain 313 mg of the target product as a white solid powder with a yield of 46.5%.
[0049] Example 2: N-(3-phenylpropyl)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-3-amine (A2)
[0050] The 3-chlorophenethylamine (1a) in Example 1 was replaced by amphetamine (1b), and the other steps were the same as in Example 1 to obtain 364 mg of the target product as a gray solid powder with a yield of 57.2%.
[0051] Example 3: N-(3,4-dichlorophenethyl)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-3-amine (A3)
[0052] The 3-chlorophenethylamine (1a) in Example 1 was replaced by 3,4-dichlorophenethylamine (1c), and the other steps were the same as Example 1 to obtain 408 mg of the target product as a light yellow solid powder. The yield was 55.7%.
[0053] Example 4: 3-((3-chlorobenzyl)amino)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-8-carboxylic acid (A4)
[0054] The 3-chlorophenylethylamine (1a) in Example 1 was replaced by 3-chlorobenzylamine (1d), and the o-phenylenediamine (5a) was replaced by 2,3-diaminobenzoic acid (5b). The other steps were the same as in Example 1 to obtain 332 mg of the target product as a gray solid powder. The yield was 45.7%.
[0055] Example 5: 3-((3-chlorobenzyl)amino)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-7-carbonitrile (A5)
[0056] The 3-chlorophenylethylamine (1a) in Example 1 was replaced by 3-chlorobenzylamine (1d), and the o-phenylenediamine was replaced by 3,4-diaminobenzonitrile (5c). Other steps were the same as in Example 1 to obtain 287 mg of the target product as a gray solid powder. The yield was 41.5%.
[0057] Example 6: 3-((3-chlorophenethyl)amino)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-8-carboxylic acid (A6)
[0058] The o-phenylenediamine (5a) in Example 1 was replaced by 2,3-diaminobenzoic acid (5b), and the other steps were the same as in Example 1 to obtain 357 mg of the target product as a white solid powder. The yield was 47.5%.
[0059] Example 7: 3-((3,4-dichlorophenethyl)amino)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-7-carboxylic acid (A7)
[0060] The 3-chlorophenethylamine (1a) in Example 1 was replaced by 3,4-dichlorophenethylamine (1c), and the o-phenylenediamine (5a) was replaced by 3,4-diaminobenzoic acid (5d). The other steps were the same as in Example 1 to obtain 317 mg of the target product as a gray solid powder. The yield was 39.0%.
[0061] Example 8: 3-((3,4-dichlorophenethyl)amino)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-7-carboxylic acid methyl ester (A8)
[0062] The 3-chlorophenethylamine (1a) in Example 1 was replaced by 3,4-dichlorophenethylamine (1c), and the o-phenylenediamine (5a) was replaced by 3,4-diaminobenzoic acid methyl ester (5e). The other steps were the same as in Example 1 to obtain 289 mg of the target product as a gray solid powder. The yield was 34.5%.
[0063] Example 9: N-(3-bromophenethyl)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-3-amine (A9)
[0064] The 3-chlorophenethylamine (1a) in Example 1 was replaced by 3-bromophenethylamine (1e), and the other steps were the same as in Example 1 to obtain 302 mg of the target product as a brown solid powder with a yield of 40.2%.
[0065] Example 10: N-(3-fluorophenethyl)-2',3',5',6'-tetrahydro-1H-spiro[quinoxaline-2,4'-thiopyran]-3-amine (A10)
[0066] The 3-chlorophenethylamine (1a) in Example 1 was replaced by 3-fluorophenethylamine (1f), and the other steps were the same as Example 1 to obtain 322 mg of the target product as a brown solid powder. The yield was 50.1%.
[0067] The preparation method of compound B1-B6 is as follows:
[0068]
[0069]
[0070] Reagent conditions: (a) ZrCl4, EtOH, 6h.
[0071] Example 11: N-(2-cyclohexylethyl)-4-methyl-1'H-spiro[cyclohexane-1,2'-quinoxaline]-3'-amine (B1)
[0072] Preparation of 7a: the same as the preparation method of 4a in Example 1.
[0073] The compound 4a in Example 1 was replaced by the compound 7a, and the compound 6 was replaced by the compound 8a, and the rest was the same as Example 1, to obtain 313 mg of the target product as a red solid powder. Yield: 31.6%.
[0074] Example 12: N-(2-cyclohexylethyl)-1'H-spiro[cyclohexane-1,2'-quinoxaline]-3'-amine (B2)
[0075] The compound 4a in Example 1 was replaced by the compound 7a, and the compound 6 was replaced by the compound 8b. The other steps were the same as in Example 1 to obtain 281 mg of the target product in the form of light red solid powder. The yield was 29.6%.
[0076] Example 13: N-(3-cyclohexylpropyl)-4-methyl-1'H-spiro[cyclohexane-1,2'-quinoxaline]-3'-amine (B3)
[0077] Preparation of 7b: the same as the preparation method of 4a in Example 1.
[0078] The compound 4a in Example 1 was replaced by the compound 7b, and the compound 6 was replaced by the compound 8a. The other steps were the same as in Example 1 to obtain 277 mg of the target product as a brown solid powder. The yield was 26.8%.
[0079] Example 14: N-(3-cyclohexylpropyl)-1'H-spiro[cyclohexane-1,2'-quinoxaline]-3'-amine (B4)
[0080] The compound 4a in Example 1 was replaced by the compound 7b, and the compound 6 was replaced by the compound 8b. The other steps were the same as in Example 1 to obtain 254 mg of the target product as a brown solid powder. The yield was 25.6%.
[0081] Example 15: N-(Cyclohexylmethyl)-1'H-spiro[cyclohexane-1,2'-quinoxaline]-3'-amine (B5)
[0082] Preparation of 7c: the same as the preparation method of 4a in Example 1.
[0083] The compound 4a in Example 1 was replaced by the compound 7c, and the compound 6 was replaced by the compound 8b. The other steps were the same as in Example 1 to obtain 338 mg of the target product as a yellow solid powder. The yield was 37.2%.
[0084] Example 16: N-(Cyclohexylmethyl)-4-methyl-1'H-spiro[cyclohexane-1,2'-quinoxaline]-3'-amine (B6)
[0085] The compound 4a in Example 1 was replaced by the compound 7c, and the compound 6 was replaced by the compound 8a. The other steps were the same as in Example 1 to obtain 347 mg of the target product as a dark red solid powder. The yield was 36.5%.
[0086] The NMR and MS data of the compounds of the present invention prepared in the above examples are shown in Table 1.
[0087] Table 1 NMR and MS data of the compounds of the present invention
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094] Effect Example 1
[0095] Instruments, materials, reagents, strains, and related pretreatment
[0096] Instruments: 4℃, -20℃ and -80℃ refrigerators, biological safety cabinets, microplate readers, 4℃, 35℃ and 37℃ constant temperature incubators, digital air bath constant temperature oscillator, low and high speed centrifuges, 2.5μL, 10μL, 20μL, 100μL and 300μL micro-adjustable pipettes, high-throughput tissue grinder.
[0097] Materials: Corning 12-, 24- and 96-well cell culture plates, 1.5 mL, 15 mL and 50 mL centrifuge tubes, 15 mL glass shake tubes, 10 μL, 200 μL and 1 mL sterile pipette tips, physiological saline, triple distilled water, 1 mL syringe, sterile sample tank, and steel balls.
[0098] Reagents: DMSO, XTT, menadione, India ink.
[0099] Strains: The strains required in the experiment were selected from common clinical pathogenic fungi: Cryptococcus neoformans H99 (C.neoformans ATCC 34877), Cryptococcus gattii (C.gattii ATCC 14116), Candida albicans (C.albicansSC5314, C.albicans 0304103), Candida glabrata (C.glabrata 9073), Candida lusitaniae (C.lusitaniae 9150), Candida tropicalis (C.tropicalis 10186), and Candida krusei (C.krusei10153).
[0100] Preparation of culture medium: The materials and methods required for the preparation of PBS buffer, RPMI 1640 culture medium, YEPD culture medium and SDA culture medium are detailed in Table 2.
[0101] Table 2 Preparation materials and methods of culture medium
[0102]
[0103]
[0104] Preparation of the drug to be tested: The drug to be tested was dissolved in DMSO to prepare a 2 mg / mL stock solution, which was stored in a -20°C refrigerator for later use.
[0105] Activation of the strain to be tested: Take out the strain to be tested frozen in a -80℃ refrigerator, quickly pick up a small amount with a 1mL pipette tip, and put it into a 15mL glass shake tube containing 1mL YEPD culture solution, and blow and mix. Then place it in a 30℃ shaking incubator for 24 hours. After that, draw 10μL from the glass shake tube into a new glass tube containing 1mL YEPD culture solution, and continue to incubate in a 30℃ shaking incubator for 16 hours to complete the activation of the strain. At this time, the fungus is in the late exponential growth stage.
[0106] Preparation of bacterial suspension: transfer the activated bacterial solution to be tested to a 1.5mL EP tube, centrifuge at 3000rpm for 1min, remove the supernatant, wash the strain with 1mL PBS, centrifuge and discard the supernatant, repeat the washing three times. According to the experimental needs, use RPMI 1640 or YEPD culture medium to dilute the test strain in the late exponential growth stage into a bacterial suspension of the required concentration.
[0107] In vitro antifungal activity test
[0108] The in vitro antifungal activity of the compounds was evaluated by the micro-liquid dilution method recommended by the Clinical and Laboratory Standards Institute (CLSI). The test strains in the late exponential growth phase were diluted to 1×10 3 cells / mL of bacterial suspension. Take a 96-well cell culture plate (columns 1-12, rows AH), add the prepared bacterial suspension to each well of columns 1-11 and rows BG, add 200μL to each well in column 1, and 100μL to each well in columns 2-11. Then add the drug solution to be tested to column 1, 6.4μL / well, and make triplicate wells. Starting from column 1, dilute by half to column 10, ten concentration gradients from 64μg / mL to 0.125μg / mL can be obtained. Among them, column 11 is a bacterial suspension without drug addition, which serves as a negative control. Blank RPMI 1640 culture medium is added to rows A, H, and 12 as blank controls. Place the 96-well cell culture plate in a 35°C constant temperature incubator and incubate for 48h (the culture time of Cryptococcus is 72h), and then measure the optical density value (OD 630 ). Let OD 630,阴性对照组 The minimum inhibitory concentration (MIC) of the compound is 100%, and the minimum concentration corresponding to the inhibition rate (%) greater than or equal to 80% is the minimum inhibitory concentration (MIC) of the compound. 80 ).
[0109] The calculation formula of the antibacterial rate (%) is:
[0110] Inhibition rate (%) = (OD 630阴性对照组 -OD 630药物组 ) / (OD 630阴性对照组 -OD 630空白对照组 )×100%
[0111] The experimental results are shown in Tables 3 and 4. Compound 1 in the patent application with publication number WO2015007730A1 was used as a comparative example, and compound 1 was tested as a control. Its in vitro antifungal activity MIC 80 =64 μg / mL; the antifungal activity of preferred compounds A1 and A3 in the present invention is 16-64 times that of compound 1.
[0112]
[0113] Table 3 In vitro antifungal activity test of compounds (MIC 80 , μg / mL)
[0114]
[0115] Note a:Abbreviations:C.neo.,Cryptococcus neoformans.
[0116] Table 4 In vitro antifungal spectrum (MIC 80 , μg / mL)
[0117]
[0118] Note a: Abbreviations: C.alb., Candida albicans; C.gla., Candida glabrata; C.lus., Candida lusitaniae; C.tro., Candida tropicalis; C.kru., Candida krusei; C.neo., Cryptococcus neoformans; C.gat., Cryptococcusgattii; FLC, fluconazole.
[0119] As shown in Tables 3 and 4, the in vitro antifungal activity test results show that most of the compounds of the present invention exhibit good antifungal activity against Cryptococcus neoformans H99, such as A1 (MIC 80 =4 μg / mL), A3 (MIC 80 =1 μg / mL), A9 (MIC 80 =4 μg / mL), A10 (MIC 80 =8μg / mL), B1(MIC 80 =8μg / mL), B2 (MIC 80 =8μg / mL), B3 (MIC 80 =4 μg / mL) and B4 (MIC 80 =4 μg / mL).
[0120] Among them, compounds A1 and A3 only have selective antifungal activity against Cryptococcus, and the anti-cryptococcal activity of compound A3 is better than that of the positive control drug FLC.
[0121] Effect Example 2: Time-growth curve measurement of compounds A1 and A3
[0122] Cryptococcus neoformans H99 in the late exponential growth phase was diluted to 2×10 6 Take a 96-well cell culture plate, add 200 μL of bacterial suspension to each well A1-C1, add 100 μL of blank RPMI 1640 to each well in rows AC, and start diluting from column 1 by half, and measure the OD 630 Value. Use each well OD 630 The standard curve was made by combining the value and the corresponding bacterial concentration. 5 mL of the prepared bacterial suspension was added to several 15 mL centrifuge tubes, and then FLC, compound A1 and A3 were added. Four dosing concentrations were set for each group, namely 4 μg / mL, 8 μg / mL, 16 μg / mL and 32 μg / mL. Another tube was taken without adding the drug as a blank control. The samples were placed in a 30 ° C constant temperature oscillator for shaking culture at a speed of 220 rpm, and 100 μL was drawn from each sample tube into a 96-well cell culture plate (triplicate wells) at 0 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, and 48 h, and the OD was measured. 630 The corresponding bacterial concentration was calculated by the standard curve and the lg value was taken. The experimental results were plotted using GraphPad Prism 8. Figure 1 As shown, Figure 1 Schematic diagram of the time-growth curve results of compounds A1 and A3 acting on Cryptococcus neoformans.
[0123] The time-growth curve results of compounds A1 and A3 on Cryptococcus neoformans H99 showed that compounds A1 and A3 had inhibitory effects on the growth of Cryptococcus neoformans, and the inhibitory effect of compound A1 was equivalent to that of FLC.
[0124] Effect Example 3: Experiment on the inhibition of biofilm formation of Cryptococcus neoformans by compounds A1 and A3
[0125] Cryptococcus neoformans H99 in the late exponential growth phase was diluted to 1×10 6cells / mL of bacterial suspension. Take a 96-well cell culture plate (columns 1-12, rows AH), add the prepared bacterial suspension to each well of columns 1-11 and rows BG, 100 μL per well, and incubate at 37°C for 1.5 hours. Take another 96-well cell culture plate, add blank RPMI 1640 culture medium to each well of columns 1-12 and rows BG, add 300 μL to each well of B1-G1, and 150 μL to each well of the remaining wells, and add FLC, compounds A1 and A3 to column 1, and make triplicate wells. Start from column 1 and dilute by half to column 10 to prepare a drug solution with a final concentration of 64 μg / mL to 0.125 μg / mL. The upper layer of culture fluid in the 96-well cell culture plate that has been cultured for 1.5 hours was aspirated and discarded, and the plate was washed three times with PBS buffer. The prepared drug solution was then transferred to the plate, 100 μL per well. The 11th and 12th columns were used as negative controls and blank controls, respectively, and the plate was placed in a 37°C incubator for continued culture. After 24 hours of culture, the upper layer of drug solution was gently aspirated and discarded, and the plate was washed three times with PBS buffer. Freshly prepared XTT / menadione solution was added to each well, 150 μL per well, and cultured at 37°C in the dark. After 3 hours, 80 μL was aspirated from each well along the wall into a new 96-well cell culture plate, and its OD was measured. 492 Compared with the negative control group, the OD 492 The lowest drug concentration corresponding to a decrease of 80% or more is the minimum inhibitory concentration (SMIC) of the drug. 80 GraphPad Prism 8 was used for graphing and paired sample t-test was used for statistical analysis.
[0126] The experimental results are as follows Figure 2 As shown, Figure 2 Schematic diagram of the inhibitory effect of compounds A1 and A3 on the biofilm formation of Cryptococcus neoformans. Compounds A1 and A3 have a significant inhibitory effect on the biofilm formation of Cryptococcus neoformans H99. The inhibition rate of 16μg / mL of compound A1 and 8μg / mL of compound A3 on the formation of Cryptococcus neoformans H99 biofilm is greater than 80%; at high concentrations (≥32μg / mL), the inhibition rate of compounds A1 and A3 on the formation of Cryptococcus neoformans H99 biofilm is nearly 100%, and the inhibitory effect is better than FLC.
[0127] Effect Example 4: Experiment on Cryptococcal meningitis infection model in mice using compounds A1 and A3
[0128] Mice were inoculated with Cryptococcus neoformans H99 via tail vein injection at a dose of 2×10 5cells / mouse, establish a mouse cryptococcal meningitis infection model. After 24 hours of infection, physiological saline and the prepared drug solution were administered by intraperitoneal injection and gavage. The mice were divided into five groups, the intraperitoneal injection group was a blank control group (physiological saline), FLC group (20 mg / kg), A1 group (20 mg / kg) and A3 group (20 mg / kg), and the gavage group was A3 group (20 mg / kg), and the drug was administered continuously for 5 days. On the 6th day, the mice were killed and the brain was weighed, placed in a 1.5mL thickened EP tube, two small steel beads were added, and ground with a high-throughput tissue grinder. After the brain tissue fluid was diluted with physiological saline for a certain multiple, it was spread on the SDA culture medium and cultured at 30°C for 48 hours. The bacterial load in the mouse brain was calculated by counting the number of single colonies on SDA plates and plotted using GraphPad Prism 8. Statistical analysis was performed using ANOVA and post hoc tests (Bonferroni and Student-Newman-Keuls').
[0129] The experimental results are as follows Figure 3 As shown, Figure 3 The figure is a schematic diagram of the experimental results of the mouse cryptococcal meningitis infection model of compounds A1 and A3. Compared with the blank control group, intraperitoneal injection of compounds A1 (*P<0.05) and A3 (**P<0.01) can significantly reduce the bacterial load in the mouse brain; oral administration of compound A3 has the best therapeutic effect, and the bacterial load in the mouse brain is significantly reduced (***P<0.001).
[0130] In summary, some compounds of the present invention have good in vitro anti-Cryptococcus neoformans activity, and preferably compounds A1 and A3 have good in vivo therapeutic effects on mice infected with cryptococcal meningitis.
[0131] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.
Claims
1. A quinoxaline derivative or a pharmaceutically acceptable salt thereof having antifungal activity, characterized in that: The structure of the quinoxaline derivative having antifungal activity is selected from the following structures:
2. Use of a quinoxaline derivative or a pharmaceutically acceptable salt thereof having antifungal activity in the preparation of an antifungal drug, characterized in that: The fungus is selected from Cryptococcus neoformans; The structure of the quinoxaline derivative having antifungal activity is selected from the following structures:
